2978 - Assessment of quality of life in patients with cancer and diabetes 2 in Northern Greece.

Background

Cancer and diabetes are prevalent diseases worldwide. The purpose of this study was to assess quality of life and the factors influence it in the individuals with coexistence diabetes type 2 and cancer.

Methods

A cross-sectional study was conducted in a large hospital in a major Greek city. Convenience sample of 101 patients with cancer and diabetes type 2 undergoing chemotherapy constituted the study group. Quality of life was measured by the Audit of Diabetes Depedent-QoL-Questionnaire (ADDQoL-19). Information on social-demographic, treatment of tumors and diabetes, and other clinical characteristics were collected by other questionnaire. Descriptive statistics were used for demographic characteristics. For data that were not normally distributed, nonparametric tests (Mann-Whitney U test, Kruskal-Wallis test) were applied.

Results

The majority of patients had cancer stage II (n = 52, 51,5%) and diabetes 2 for almost seven years. Individuals with coexistence of diabetes 2 and cancer reported that disease affected the overall quality of life (1.84±1.18). Also, there is a negative score in other subscale as freedom to eat (-1.43 ±0.80) and financial situation (-1.25±0,84). It was found that cancer’s stage influences the general quality of life domain (p = 0.023). Also, there were statistical significant differences between type of regimen for diabetes and several domains of quality of life. More particular, working life (p = 0.004), family life (p = 0.003), friendship and social life (p = 0.005), physical health (p = 0.003), leisure activities (p = 0.004) and financial situation (p = 0.004) are some of these domains that they are further influenced. Additionally the family status influences self-confidence (p = 0.001) and motivation (p = 0.007).

Conclusions

Taking all the above under consideration, we conclude that social-demographic and clinical characteristics were associated with quality of life in patients with cancer and diabetes 2.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.